Human papillomavirus and cancer prevention: Gaps in knowledge and prospects for research, policy, and advocacy

Vaccine

Volumn 30, Issue SUPPL.5, 2012, Pages

  Franco, Eduardo L ^a   de Sanjosé, Silvia ^b,c   Broker, Thomas R ^d   Stanley, Margaret A ^e   Chevarie Davis, Myriam ^a   Isidean, Sandra D ^a   Schiffman, Mark ^f  

^a MCGILL UNIVERSITY   (Canada)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Advocacy; Cancer prevention; HPV; Policy

Indexed keywords

VIRUS VACCINE;

CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; CAUSAL ATTRIBUTION; CELL CYCLE REGULATION; CELL LINEAGE; DNA INTEGRATION; DNA REPAIR; ENERGY BALANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; OROPHARYNX CANCER; PRIORITY JOURNAL; REVIEW; TUMOR BIOPSY; WART VIRUS; WORLD HEALTH ORGANIZATION;

EID: 84873057619     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.092     Document Type: Review

References (11)

1. Franco EL, Bosch FX, Cuzick J, Schiller JT, Garnett GP, Meheus A, Wright TC. Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine 2006 Aug 31;24(Suppl 3). S3/242-9.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available at: http://globocan.iarc.fr (last accessed June 2012).
3. Curado M P, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. (editors). Cancer Incidence in Five Continents, Vol. IX, IARC Scientific Publications No. 160, Lyon, IARC, 2007.
4. WHO/ICO (Institut Català d'Oncologia) Information Centre on HPV and Cervical Cancer. http://www.who.int/hpvcentre/en/(last accessed June 2012).
5. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006 Aug 31;24(Suppl 3). S3/11-25.
6. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010 Nov;11(11):1048-56.
7. Zuna RE, Tuller E, Wentzensen N, Mathews C, Allen RA, Shanesmith R, et al. HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer. Infect Agent Cancer 2011 Oct 28;6:19.
8. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009 Feb;112(2):293-9.
9. Mirabello L, Sun C, Ghosh A, Rodriguez AC, Schiffman M, Wentzensen N, et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population. J Natl Cancer Inst 2012 Apr 4;104(7): 556-65.
10. Van Tine BA, Kappes JC, Banerjee NS, Knops J, Lai L, Steenbergen RD, et al. Clonal selection for transcriptionally active viral oncogenes during progression to cancer. J Virol 2004 Oct;78(20):11172-86.
11. Poland GA, Jacobson RM. The clinician's guide to the anti-vaccinationists' galaxy. Hum Immunol 2012 Apr 12. [Epub ahead of print].